GSK2033 [1221277-90-2]
Cat# T15427-1mg
Size : 1mg
Brand : TargetMol
Contact local distributor :
Phone : +1 850 650 7790
GSK2033
Copy Product Info
GSK2033 is an antagonist of LXR (pIC50s: 7 and 7.4 for LXRα or LXRβ, respectively).
Cas No. 1221277-90-2
For research use only—not for human use. No sales to individuals. Use as intended only.
Select Batch
Purity:99.70%
Appearance:Solid
Color:Yellow
COA HNMR LCMS
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | GSK2033 is an antagonist of LXR (pIC50s: 7 and 7.4 for LXRα or LXRβ, respectively). |
| Targets & IC50 | LXRα:7 (pic50), LXRβ:7.4(pic50) |
| In vitro | GSK2033 dose-dependently inhibits basal transcription in full-length LXRα or full-length LXRβ cotransfection assays (IC50s: 17 nM and 9 nM, respectively). GSK2033 also effectively inhibits the transcription of an ABCA1 driven luciferase reporter dose-dependently (IC50s: 52 nM for LXRα and 10 nM for LXRβ). GSK2033 also suppresses the expression of both of fatty acid synthase (FASN) and SREBP1[2]. |
| In vivo | GSK2033 (one month) treatment, does not have obviously effects on hepatic triglyceride levels. GSK2033 treatment also have no effects on plasma triglyceride levels[2]. |
| Molecular Weight | 591.66 |
| Formula | C29H28F3NO5S2 |
| Cas No. | 1221277-90-2 |
| Smiles | Cc1cc(C)c(c(C)c1)S(=O)(=O)N(Cc1ccc(o1)C(F)(F)F)Cc1ccc(cc1)-c1cccc(c1)S(C)(=O)=O |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| Solubility Information | DMSO: 11.9 mg/mL (20.11 mM), Sonication is recommended.  | |||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1.19 mg/mL (2.01 mM), Suspension. 10% DMSO+90% Saline: < 1.19 mg/mL (2.01 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||